LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
검색
Dailypharm Live Search
Close
Managed Entry Agreements for
Managed Entry Agreements for
Oncology Drugs
Input Time : 2019-11-15
[Download file]
go back
OPINION
[Reporter’s View] Deadlines are set for a reason
Reporter's view |
Eo, Yun-Ho
Expanding NIP to include 9-vHPV
Reporter's view |
Whang, byung-woo
Creating a virtuous cycle for K-bio growth
Reporter's view |
Son, Hyung Min
INTERVIEW
"JAK inhibitors bring a paradigm shift to RA treatment"
"An OTC drug increases lymphedema patient satisfaction"
‘Era of once-weekly growth hormones…adherence is key’
Masanobu Kawai, Professor at Osaka Women's and Children's Hospital
"New targeted therapies for bile duct cancer are in need"
AstraZeneca seeks mutual growth through open collaboration
with Korea’s pharmaceutical industry
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
RNAi therapeutic 'Givlaari' receives the ODD in KOR
2
Oxlumo receives orphan drug designation in Korea
3
"Multiple myeloma dynamics require changes to reimb strategy
4
Therapeutic device 'improves OS for lung cancer patients'
5
Dongkook receives reimb for s-amlodipine triple-drug combo
6
2nd GIFT drug Nefecon’s approval imminent in Korea
7
Consumers use tricks to receive Wegovy prescriptions
8
Will combination therapies for cancer be reimbursed in KOR?
9
MFDS grants EUA to COVID-19 variant vaccine for infants
10
Illegal errand companies deliver Wegovy for ₩10,000
